As would be expected, despite samples having been taken pre-vaccination, post-COVID-19 patients also had detectable antibodies against the receptor binding domain (RBD) of SARS-CoV-2’s spike protein, with IgA and IgG abundance in the BAL, and IgG in the plasma (Figure 6E). Here, CD79A is linked to COVID-19.